RAB44, member RAS oncogene familyGenealiases: RASD3 · RASL13 · dJ431A14.3
Q-omics provides the consensus-scored RAB44 profile across patient tissues and cancer cell-line models. RAB44 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RAB44 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, RAB44 protein abundance shows 18,129 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, THCA, and PDAC as cancer lineages where RAB44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB44 survival associations across molecular data types. RAB44 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB44 RNA expression–survival associations across cancer types. High RAB44 expression shows unfavorable associations in KIRP, DLBC and KIRC, but favorable associations in HNSC, LUAD and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RAB44 RNA expression.
This table summarizes RAB44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB44 shows lower tumor expression in LUAD, COAD, LUSC and UCEC and higher tumor expression in THCA and KIRC. The THCA box plot shows higher RAB44 RNA expression in tumor versus normal tissue (log2 FC = +0.101, t-test p < 0.001).
This table shows molecular features associated with RAB44 in patient tissues and cancer cell lines. In patient samples, RAB44 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
